Проблемы клинических исследований новых лекарств как основы современной медицины, основанной на доказательствах
- Авторы: Моисеев ВС, Moiseev VS
- Выпуск: Том 80, № 12 (2008)
- Страницы: 5-10
- Раздел: Передовая статья
- URL: https://journals.rcsi.science/0040-3660/article/view/30235
- ID: 30235
Цитировать
Полный текст
Аннотация
Ключевые слова
Список литературы
- McBride W. Thalidomide and congential abnormalities. Lancet 1961; 2: 1358.
- The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 2007; 356: 1723-1735.
- Rubin P., Rutherford J. Drugs therapy in pregnant and breast-feeding women. In: Melmon and morrellis clinical pharmacology. 4 ed. New York: McGraw-Hill; 2000. 1117-1142.
- Моисеев В. С., Кобалава Ж. Д. Уроки прерванных клинических исследований в кардиологии. Клин. исслед. лекарств. средств в России 2005; 1-2: 17-19.
- The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: effect of encainid and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 1989; 321: 406-412.
- Elliott C., Abadie R. Exploiting a research underclass in phase 1 clinical trials. N. Engl. J. Med. 2008; 358: 231-236.
- Roth B. Drugs and valvular heart disease. N. Engl. J. Med. 2007; 356(1): 6-9.
- Schade R., Andersohn F., Suissa A. Dopamine agonists and the risk of cardiac-valve Regurgitation. N. Engl. J. Med. 2007; 356(1): 29-38.
- Eichelbaum M., Ingelman-Sundberg M., Evans W. E. Pharmacogenomics and individualized drug therapy. Ann. Rev. Med. 2006; 57: 119-137.
- Moore T. J., Cohen M. R., Furberg C. D. Serious adverse drug events reported to the food and drug administration, 1998- 2005. Arch. Intern. Med. 2007; 167: 1752-1759.
- Need A. C., Motulsky A. G., Goldstein D. B. Priorities and standards in pharmacogenetic research. Nat. Genet. 2005; 37: 671-681.
- Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reaction. N. Engl. J. Med. 2008; 358(6): 637-639.
- Strom R., Kimmel S. Textbook of pharmacoepidemiology. Chichester: Wiley & Sons; 2006.
- Avorn J. Dangerous deception - hiding the evidence of adverse drug effects. N. Engl. J. Med. 2006; 355: 2169-2171.
- Kjekshus J. et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 2007; 357: 2248-2261.